Drug Trial Radar · NCT06011317
A Study of EDG-7500 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Jul 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Aug 14, 2023
Primary completion
May 23, 2024
Study completion Jun 20, 2024
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purposes of this Phase 1 study of EDG-7500 are to: 1. Learn about the safety of EDG-7500 after a single and multiple doses in healthy adults 2. Learn about how EDG-7500 is tolerated after a single and multiples doses in healthy adults 3. Evaluate the amount of EDG-7500 is in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-7500 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-7500 in the blood is similar for the suspension and tablet forms of EDG-7500 in healthy adults Participants will receive a single or multiple doses of EDG-7500 or a placebo by mouth.
Conditions
- Healthy Subjects
Interventions
EDG-7500Drug
EDG-7500 is administered orally once daily
PlaceboDrug
Placebo is administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: incidence of treatment-emergent adverse eventsTime frame: Up to 25 days of monitoring
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.